Pan-cancer whole-genome analyses of metastatic solid tumours
暂无分享,去创建一个
S. Sleijfer | E. Cuppen | E. de Bruijn | E. Smit | P. Roepman | E. Voest | V. Tjan-Heijnen | C. V. van Herpen | W. Onstenk | H. Bloemendal | M. Lolkema | M. Lolkema | P. Priestley | J. Baber | N. Steeghs | K. Duyvesteyn | S. Haidari | C. Shale | M. Voda | M. Labots | P. Witteveen | A. van Hoeck | V. Tjan-Heijnen | E. Voest | Jonathan Baber | Korneel Duyvesteyn | Susan Haidari | Mircea Voda | Ewart de Bruijn | Arne van Hoeck
[1] S. Sleijfer,et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies , 2019, Nature Genetics.
[2] S. Sleijfer,et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs , 2019, Nature.
[3] Lincoln D Stein,et al. The International Cancer Genome Consortium Data Portal , 2019, Nature Biotechnology.
[4] S. Morganella,et al. A Compendium of Mutational Signatures of Environmental Agents , 2019, Cell.
[5] Takafumi N. Yamaguchi,et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact , 2019, Nature Communications.
[6] Johannes G. Reiter,et al. Minimal functional driver gene heterogeneity among untreated metastases , 2018, Science.
[7] N. Schultz,et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] Marc Salit,et al. Determining Performance Metrics for Targeted Next-Generation Sequencing Panels Using Reference Materials. , 2018, The Journal of molecular diagnostics : JMD.
[9] J. Carpten,et al. Abstract 437: Leveraging new methods in single-cell copy number analysis and clonotype detection to uncover and characterize hidden subclones within standard cell lines , 2018, Molecular and Cellular Biology / Genetics.
[10] Christopher W. Whelan,et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing , 2018, Cell.
[11] B. Taylor,et al. Genome doubling shapes the evolution and prognosis of advanced cancers , 2018, Nature Genetics.
[12] Jessica L. Davis,et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.
[13] C. Sander,et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets , 2018, Nature Genetics.
[14] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[15] Ashton C. Berger,et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. , 2018, Cancer cell.
[16] Steven J. M. Jones,et al. Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.
[17] Steven J. M. Jones,et al. Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.
[18] Michael C. Heinold,et al. The landscape of genomic alterations across childhood cancers , 2018, Nature.
[19] Xin Zhou,et al. Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors , 2018, Nature.
[20] Yu-Chih Liang,et al. ZFP36L1 and ZFP36L2 inhibit cell proliferation in a cyclin D-dependent and p53-independent manner , 2018, Scientific Reports.
[21] Astrid Gall,et al. Ensembl 2018 , 2017, Nucleic Acids Res..
[22] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[23] Chuang Tan,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.
[24] Mauricio O. Carneiro,et al. Scaling accurate genetic variant discovery to tens of thousands of samples , 2017, bioRxiv.
[25] Edwin Cuppen,et al. MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2016, Genome Medicine.
[26] G. Getz,et al. The whole-genome panorama of cancer drivers , 2017, bioRxiv.
[27] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[28] T. E. Wilson,et al. Fragile sites in cancer: more than meets the eye , 2017, Nature Reviews Cancer.
[29] Icgc,et al. Pan-cancer analysis of whole genomes , 2017, bioRxiv.
[30] Johannes G. Reiter,et al. Origins of lymphatic and distant metastases in human colorectal cancer , 2017, Science.
[31] P. Lønning,et al. Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.
[32] Robert J. Lonigro,et al. Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.
[33] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[34] Michael P. Schroeder,et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.
[35] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[36] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[37] Timothy L. Tickle,et al. STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq , 2017, bioRxiv.
[38] B. Taylor,et al. Implementing Genome-Driven Oncology , 2017, Cell.
[39] N. McGranahan,et al. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.
[40] Michael L. Gatza,et al. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer , 2017, Breast Cancer Research and Treatment.
[41] M. Rubin,et al. Non-coding genetic variation in cancer. , 2017, Current opinion in systems biology.
[42] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[43] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.
[44] Mingming Jia,et al. COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..
[45] S. Sleijfer,et al. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. , 2017, The oncologist.
[46] A. Hoischen,et al. Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags. , 2016, The Journal of molecular diagnostics : JMD.
[47] B. Leggett,et al. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis , 2016, Oncotarget.
[48] F. Silvestris,et al. NETs: organ-related epigenetic derangements and potential clinical applications , 2016, Oncotarget.
[49] E. Ratner,et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression , 2016, Molecular Cancer Therapeutics.
[50] A. Sablina,et al. Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism. , 2016, Cancer cell.
[51] Steven J. M. Jones,et al. A somatic reference standard for cancer genome sequencing , 2016, Scientific Reports.
[52] Xiaoyu Chen,et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..
[53] L. Wessels,et al. OncoScape: Exploring the cancer aberration landscape by genomic data fusion , 2016, Scientific Reports.
[54] Crispin J. Miller,et al. Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. , 2016, Cancer research.
[55] Ricardo Villamarín-Salomón,et al. ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..
[56] Hanlee P. Ji,et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.
[57] R. Kuick,et al. The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia. , 2015, Immunity.
[58] B. Teh,et al. MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations , 2015, Scientific Reports.
[59] M. Nykter,et al. The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.
[60] Jindan Yu,et al. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer , 2015, Genes & diseases.
[61] Gang Fu,et al. Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data , 2014, Nucleic Acids Res..
[62] Roman K. Thomas,et al. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer , 2014, Clinical Cancer Research.
[63] M. van de Rijn,et al. Dystrophin Is a Tumor Suppressor in Human Cancers with Myogenic Programs , 2014, Nature Genetics.
[64] S. Willems,et al. p16INK4A and p14ARF Gene Promoter Hypermethylation as Prognostic Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma: A Review , 2014, Disease markers.
[65] S. Elledge,et al. Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.
[66] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[67] Mauricio O. Carneiro,et al. From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.
[68] S. Gabriel,et al. Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.
[69] C. Klein. Selection and adaptation during metastatic cancer progression , 2013, Nature.
[70] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[71] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[72] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[73] D. Busam,et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. , 2013, Cancer research.
[74] A. Børresen-Dale,et al. Copynumber: Efficient algorithms for single- and multi-track copy number segmentation , 2012, BMC Genomics.
[75] Melissa E. Ko,et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer , 2012, Proceedings of the National Academy of Sciences.
[76] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[77] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[78] A. McKenna,et al. Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.
[79] Syed Haider,et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.
[80] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[81] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.
[82] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[83] Elias Campo Guerri,et al. International network of cancer genome projects , 2010, Nature.
[84] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[85] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[86] L. Senelick. It (review) , 2008 .
[87] S. Nee. More than meets the eye , 2004, Nature.
[88] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[89] J. Gebert,et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families , 2001, Gut.
[90] S. Bull,et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.
[91] M. Krečmerová,et al. Lipases as Tools in the Synthesis of Prodrugs from Racemic 9-(2,3-Dihydroxypropyl)adenine , 2012, Molecules.
[92] F. Waldman,et al. Y chromosome loss detected by FISH in bladder cancer. , 1995, Cancer genetics and cytogenetics.
[93] S. Hunter,et al. Y chromosome loss in esophageal carcinoma: An in situ hybridization study , 1993, Genes, chromosomes & cancer.
[94] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.